Keymed Biosciences Inc. has announced the publication of the latest clinical trial results for their bispecific antibody treatment, CM336, in the New England Journal of Medicine. Conducted by Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, the study reports on the efficacy of CM336 in treating patients with refractory autoimmune hemolytic anemia (AIHA) following CD19 CAR T-Cell Therapy. Two patients showed rapid disease improvement, achieving partial remission within days and maintaining sustained remission for over six months without further immunosuppressive therapies. The study highlights CM336's potential as a treatment option, demonstrating positive efficacy signals and a favorable safety profile.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。